Patch testing to plants: sensitisation associated with exposure to plants, essential oils and botanicals in cosmetics.

BACKGROUND: Contact allergy to plants, particularly Compositae, presents with dermatitis and is diagnosed with skin patch testing. Sesquiterpene lactone mix is a common screening allergen for plant allergy. The rate of plant allergen sensitisation in New Zealand, which is affected by local horticultural factors, has not previously been documented. AIMS: To investigate the rate of plant allergen sensitisation in New Zealand's regional population, characterise common allergens and reassess appropriate allergens for patch testing. METHODS: Retrospective analysis of patient demographics and patch-test results over an eight-year period (2012 to 2020) was performed at a tertiary patch-test clinic in Auckland, New Zealand. RESULTS: 820 patients completed patch testing. There was a 12.9% sensitivity rate (a positive reaction on patch testing) to at least one plant allergen and a 6.2% plant allergy rate (positive reaction of current relevance). The most frequent positive reactions were Myroxylon pereirae (n=38), colophonium (n=35) and sesquiterpene lactone mix (n=14). Of patients with a plant allergy (n=51), the allergy source was a botanical in a cosmetic product in 27 cases (52.9%), a plant in ten (19.6%) and an essential oil in two (3.9%). CONCLUSIONS: Reactions to plant allergens were related to botanicals in cosmetics and creams, plants and essential oils. Rates of plant sensitisation in our cohort are comparable with international data.

Topical corticosteroid allergy: Results of sequential testing to a corticosteroid series in New Zealand.

BACKGROUND: Our institution tests the European Baseline Series (EBS) and a steroid series sequentially in all patients presenting for patch testing. The rate of steroid sensitization in New Zealand has not previously been documented. OBJECTIVES: To investigate the rate of corticosteroid sensitization and assess additional benefit of testing the full steroid series over the steroid allergy markers in the EBS. METHODS/PATIENTS: Retrospective analysis of all patient demographics and patch test results over a 5-year period (2014 to 2019) was performed at a tertiary patch test clinic in Auckland, New Zealand. RESULTS: A total of 319 patients completed patch testing, and 4.4% were sensitized to one or more corticosteroids. As much as 79% of positive reactions were of current relevance; 11/14 reactions were to tixocortol pivalate or budesonide. The "number needed to test" to detect one additional case of corticosteroid sensitization by using the full corticosteroid series over the EBS alone was 107. CONCLUSIONS: Although corticosteroid sensitization was not uncommon in our population, the results suggest that sequential testing with the corticosteroid markers (budesonide and tixocortol) in the standard series alone is adequate. The additional corticosteroid series should be added if the markers are positive or where there is a clinical suspicion of corticosteroid allergy.

Contact allergy to progesterone and estradiol in a patient with multiple corticosteroid allergies.

A 61-year-old woman with a persistent hand and foot dermatitis developed multiple contact allergies to topical steroids. She had a past history of allergic contact dermatitis (ACD) to a hormone replacement patch containing both estrogen and progesterone. The aim of this report is to highlight the potential cross-reactions between topical corticosteroids and sex steroids. Patch testing with a standard series, a corticosteroid series, and the sex steroids progesterone and estradiol was performed. Positive ACD reactions to hydroxyprogesterone, progesterone, and estradiol occurred. There were also multiple corticosteroid allergies. This case demonstrates that patients who develop contact allergies to sex steroids are at risk of developing multiple corticosteroid allergies.

Leg ulceration after pulsed dye laser treatment of a vascular malformation.

BACKGROUND AND OBJECTIVES: The pulse dye laser (PDL) is a well-established treatment for port wine stains (PWSs) and is generally accepted to be safe, effective, and results in fading in the majority of patients. Significant side effects such as scarring are extremely rare. To date ulceration has not been reported. STUDY DESIGN/PATIENTS AND METHODS: We report a 22-year-old male who presented with a large vascular malformation on his lower leg with both superficial capillary and deeper venous components, which on venography and ultrasound showed abnormal architecture and reflux into the superficial collecting system. He underwent a series of test areas with the PDL on the lower leg. RESULTS: Ulceration developed in multiple sites after treatment as well as significant symptoms and signs of varicose eczema, which took at least 2 months to heal despite appropriate topical treatments and compression. CONCLUSIONS: Patients with vascular malformations of the lower leg with deeper venous components should be warned about the development of ulceration and treated with caution.

Pharmacoeconomics of drug therapy for atopic dermatitis.

Atopic dermatitis is an increasingly prevalent common childhood disease. While the majority of patients have mild disease, atopic dermatitis can cause considerable distress to patients and their caregivers, with significant social and financial cost to families. With a prevalence of 15 - 20% in Western countries, atopic dermatitis also has a considerable health and societal cost to the community. Many new treatments have been shown to be therapeutically effective, particularly in severe disease, including cyclosporin A (Neoral, Novartis AG), interferon, tacrolimus (Fujisawa Pharmaceutical Co. Ltd.) and iv. immunoglobulin. These are expensive when compared to standard treatments like emollients and topical corticosteroids and have significant adverse effects that limit their use. Additional costs related to monitoring are incurred and the long-term safety of these treatments is yet to be determined. However, an advantage over more traditional therapies is their ability to produce benefits even after treatment ceases. Treatments that produce long-term remissions have a greater likelihood of being cost-effective. With monetary constraints on healthcare and the importance governments place on reducing drug costs, economic evaluations are becoming an increasingly important factor for drug acceptance. Those evaluating cost-effectiveness should pay particular attention to the potential reduction in indirect and intangible costs. Unfortunately, there is a dearth of cost-effectiveness studies in atopic eczema and this needs to be addressed with some urgency.